| Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis S Yoshida, S Tsutsumi, G Muhlebach, C Sourbier, MJ Lee, S Lee, ... Proceedings of the National Academy of Sciences 110 (17), E1604-E1612, 2013 | 271 | 2013 |
| Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2 Y Hasumi, M Baba, R Ajima, H Hasumi, VA Valera, ME Klein, DC Haines, ... Proceedings of the National Academy of Sciences 106 (44), 18722-18727, 2009 | 255 | 2009 |
| Identification and characterization of a novel folliculin-interacting protein FNIP2 H Hasumi, M Baba, SB Hong, Y Hasumi, Y Huang, M Yao, VA Valera, ... Gene 415 (1-2), 60-67, 2008 | 216 | 2008 |
| Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn H Hasumi, M Baba, Y Hasumi, M Lang, Y Huang, HBF Oh, M Matsuo, ... Proceedings of the National Academy of Sciences 112 (13), E1624-E1631, 2015 | 110 | 2015 |
| Regulation of Mitochondrial Oxidative Metabolism by Tumor Suppressor FLCN H Hasumi, M Baba, Y Hasumi, Y Huang, H Oh, RM Hughes, ME Klein, ... Journal of the National Cancer Institute 104 (22), 1750-1764, 2012 | 103 | 2012 |
| Genetic, epidemiologic and clinicopathologic studies of Japanese Asian patients with Birt–Hogg–Dubé syndrome M Furuya, M Yao, R Tanaka, Y Nagashima, N Kuroda, H Hasumi, M Baba, ... Clinical Genetics 90 (5), 403-412, 2016 | 101 | 2016 |
| Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells H Uemura, H Ishiguro, Y Nagashima, T Sasaki, N Nakaigawa, H Hasumi, ... Molecular cancer therapeutics 4 (11), 1699-1709, 2005 | 88 | 2005 |
| Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer H Uemura, H Hasumi, T Kawahara, S Sugiura, Y Miyoshi, N Nakaigawa, ... International Journal of Clinical Oncology 10, 405-410, 2005 | 86 | 2005 |
| The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dube syndrome is required for murine B-cell development M Baba, JR Keller, HW Sun, W Resch, S Kuchen, HC Suh, H Hasumi, ... Blood, The Journal of the American Society of Hematology 120 (6), 1254-1261, 2012 | 72 | 2012 |
| Birt–Hogg–Dube syndrome: clinical and molecular aspects of recently identified kidney cancer syndrome H Hasumi, M Baba, Y Hasumi, M Furuya, M Yao International journal of urology 23 (3), 204-210, 2016 | 71 | 2016 |
| Renin‐angiotensin system is an important factor in hormone refractory prostate cancer H Uemura, H Hasumi, H Ishiguro, J Teranishi, Y Miyoshi, Y Kubota The Prostate 66 (8), 822-830, 2006 | 71 | 2006 |
| Adipocyte‐derived monocyte chemotactic protein‐1 (MCP‐1) promotes prostate cancer progression through the induction of MMP‐2 activity Y Ito, H Ishiguro, N Kobayashi, H Hasumi, M Watanabe, M Yao, H Uemura The Prostate 75 (10), 1009-1019, 2015 | 64 | 2015 |
| Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation Y Hasumi, M Baba, H Hasumi, Y Huang, M Lang, R Reindorf, H Oh, ... Human molecular genetics 23 (21), 5706-5719, 2014 | 64 | 2014 |
| FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma N Nakaigawa, K Kondo, U Tateishi, R Minamimoto, T Kaneta, K Namura, ... BMC cancer 16, 1-7, 2016 | 59 | 2016 |
| PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer T Kawahara, Y Ishiguro, S Ohtake, I Kato, Y Ito, H Ito, K Makiyama, ... BMC urology 18, 1-6, 2018 | 56 | 2018 |
| Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study RJ Motzer, C Porta, M Eto, T Powles, V Grünwald, TE Hutson, B Alekseev, ... Journal of Clinical Oncology 42 (11), 1222-1228, 2024 | 53 | 2024 |
| TFE3 Xp11. 2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease M Baba, M Furuya, T Motoshima, M Lang, S Funasaki, W Ma, HW Sun, ... Molecular Cancer Research 17 (8), 1613-1626, 2019 | 52 | 2019 |
| Tumor signatures of PTHLH overexpression, high serum calcium, and poor prognosis were observed exclusively in clear cell but not non clear cell renal carcinomas M Yao, T Murakami, K Shioi, N Mizuno, H Ito, K Kondo, H Hasumi, F Sano, ... Cancer medicine 3 (4), 845-854, 2014 | 48 | 2014 |
| 1.5 µm Multiple quantum well distributed feedback laser diodes grown on corrugated InP by MOVPE M Kitamura, S Takano, N Henmi, T Sasaki, H Yamada, H Hasumi, I Mito Conference on Lasers and Electro-Optics, CPD11, 1988 | 45 | 1988 |
| Birt‐Hogg‐Dubé syndrome‐associated renal cell carcinoma: Histopathological features and diagnostic conundrum M Furuya, H Hasumi, M Yao, Y Nagashima Cancer science 111 (1), 15-22, 2020 | 33 | 2020 |
